GPCR Structure Therapeutics Inc. American
Company Analysis
Latest News
🔴 Structure Therapeutics is trading 4.1% down today amid a 2.11% biotech-sector decline
Structure Therapeutics is trading 4.1% down at $37.37, with the move appearing primarily sector-driven as biotech falls 2.11%. - No newly reported...
🟢 Structure Therapeutics is trading 4.4% up in pre-market as major indices rise ahead of inflation report
Structure Therapeutics is trading 4.4% up at $41.30, with the pre-market rebound appearing aligned with firmer broader-market sentiment ahead of the scheduled...
🔴 Structure Therapeutics is trading 4% down today after hotter-than-expected producer inflation
Structure Therapeutics is trading 4.03% down at $39.57 as broader markets weaken after hotter-than-expected producer inflation and rising Treasury yields. -...
🟢 Structure Therapeutics is trading 11% up today after aleniglipron delivered up to 16.2% weight loss
Structure Therapeutics is trading 10.53% up now at $44.63 after September 8, 2026 clinical updates showed aleniglipron delivering up to 16.2% mean weight loss...
🟢 Structure Therapeutics is trading 6.7% up today after aleniglipron delivered up to 16.2% weight loss
Structure Therapeutics is trading 6.66% up now at $43.07 after September 8, 2026 clinical updates showed aleniglipron delivered up to 16.2% mean weight loss at...
Structure Therapeutics' Obesity Data Sparks a Rebound, but Can an Oral Pill Compete in a Crowded Injectable Market?
Shares of Structure Therapeutics surged 6.1% to $42.84 in early trading on September 9, clawing back ground after a punishing 14.7% drop the session before — a...
🟢 Structure Therapeutics is trading 6.09% up in pre-market after positive aleniglipron and ACCG-2671 data
Structure Therapeutics is trading 6.09% up in pre-market at $42.84 after positive clinical data for oral obesity treatments aleniglipron and ACCG-2671. -...
🔴 Structure Therapeutics is trading 10.08% down today amid broader risk-off sentiment despite positive clinical data
Structure Therapeutics is trading 10.08% down at $42.57 after a broader risk-off session in U.S. equities, with geopolitical tensions, higher oil prices,...
🔴 Structure Therapeutics is trading 4.3% down today despite positive September 8 clinical data
Structure Therapeutics is trading 4.3% down at $45.28 after a broader risk-off session in U.S. equities. - Geopolitical tensions, higher oil prices, tariff...
Structure Therapeutics Reports Positive Clinical Data for Oral Weight Loss Drug Candidates
Structure Therapeutics (GPCR) announced positive topline clinical trial results for two oral small molecule candidates for chronic weight management: ACCG-2671...
🟢 Structure Therapeutics is trading 4.05% up today with no clear catalyst identified
Structure Therapeutics is trading 4.05% up at $47.77, with no clear catalyst identified for September 1, 2026. - No company-specific announcement, clinical...
🔴 Structure Therapeutics is trading 4.07% down with no company-specific catalyst identified
Structure Therapeutics is trading 4.07% down now at $45.44, with no new company-specific announcement or clinical, regulatory, earnings, or analyst catalyst...
🔴 Structure Therapeutics falls 4.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Structure Therapeutics falls 4.4% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Structure Therapeutics is trading 4.3% up in pre-market as biotech stocks rally broadly
Structure Therapeutics is trading 4.3% up at $56.47 after biotechnology stocks rallied broadly in pre-market trading. - The latest official update was August...
🔴 Structure Therapeutics is trading 5% down in after-hours trading with no clear catalyst identified
Structure Therapeutics is trading 4.94% down now at $52.00 after closing at $54.70 on August 13, 2026, with no clear company-specific catalyst identified. -...
🔴 Structure Therapeutics is trading 7.92% down in after-hours trading
Structure Therapeutics is trading 7.92% down in after-hours trading at $48.00, with no reliable company-specific announcement or late-breaking event identified...
🟢 Structure Therapeutics is trading 5% up in pre-market after Phase 3 ACCOMPLISH dosing
Structure Therapeutics is trading at $55.72, +4.86%, after announcing Phase 3 ACCOMPLISH dosing for aleniglipron in obesity trials. - Up to 4,700 patients are...
Structure Therapeutics initiates Phase 3 obesity trials and reports $1.3B cash in second quarter 2026
Structure Therapeutics reported a net loss of $106.2 million for the second quarter 2026, driven by a substantial increase in research and development...
🟢 Structure Therapeutics rises 4.0% — Biotech Sector Rallies on Argenx-Forte M&A Deal
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher, with the XBI ETF...